March 3 (Reuters) – The U.S. Food and Drug Administration has told Novo Nordisk to stop running a consumer ad for its blockbuster diabetes drug Ozempic, saying the commercial makes false and misleading claims about what the drug can do.
It is the second time in less than a month that the FDA has warned the Danish drugmaker for deceptive advertising.
The latest letter, dated February 26, takes aim at an ad for Ozempic, the company’s flagship diabetes injection.
The first warning letter, issued on February 5, was about a TV spot for Wegovy, Novo’s weight-loss pill.
Novo Nordisk did not immediately respond to Reuters’ request for comment.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Shinjini Ganguli)
Brought to you by www.srnnews.com